Designing herpes viruses as oncolytics

Molecular Therapy Oncolytics

Volumn 2, Issue , 2015, Pages 15010-

  Peters, Cole ^a   Rabkin, Samuel D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; MICRORNA; NUCLEOSIDE ANALOG; ONCOLYTIC HERPES VIRUS; PROTEIN ICP0; PROTEIN ICP47; PROTEIN SERINE THREONINE KINASE; PROTEIN UL56; PROTEIN US3; RIBONUCLEOTIDE REDUCTASE; UNCLASSIFIED DRUG; URACIL DNA GLYCOSIDASE;

ARTICLE; BOVINE HERPESVIRUS 1; CANCER CELL; CANCER INHIBITION; CELL DIVISION; GENE FUNCTION; GENE MUTATION; GENE TARGETING; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; INNATE IMMUNITY; NONHUMAN; NUCLEOTIDE METABOLISM; PATHOGENICITY; PRIORITY JOURNAL; RECEPTOR BINDING; RNA PROCESSING; TISSUE CULTURE CELL; TRANSGENE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; VIRUS INFECTION; VIRUS REPLICATION;

EID: 85006118797     PISSN: None     EISSN: 23727705     Source Type: Journal    
DOI: 10.1038/mto.2015.10     Document Type: Review

References (184)

1. Russell, SJ, Peng, KW and Bell, JC (2012). Oncolytic virotherapy. Nat Biotechnol 30: 658-670.
2. Roizman, B, Knipe, DM and Whitley, RJ. Herpes simplex viruses. In: Knipe DM and Howley PM (eds). Fields Virology. Lippincott Williams &Wilkins, Philadelphia, 2013. pp 1823-1897.
3. Field, HJ and Wildy, P (1978). The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice. J Hyg (Lond) 81: 267-277.
4. Schubert, A, Gentner, E, Bohn, K, Schwarz, M, Mertens, T and Sauerbrei, A (2014). Single nucleotide polymorphisms of thymidine kinase and DNA polymerase genes in clinical herpes simplex virus type 1 isolates associated with different resistance phenotypes. Antiviral Res 107: 16-22.
5. Luo, C, Mori, I, Goshima, F, Ushijima, Y, Nawa, A, Kimura, H et al. (2007). Replicationcompetent, oncolytic herpes simplex virus type 1 mutants induce a bystander effect following ganciclovir treatment. J Gene Med 9: 875-883.
6. Martuza, RL, Malick, A, Markert, JM, Ruffner, KL and Coen, DM (1991). Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252: 854-856.
7. Kaplitt, MG, Tjuvajev, JG, Leib, DA, Berk, J, Pettigrew, KD, Posner, JB et al. (1994). Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats. J Neurooncol 19: 137-147.
8. Jia, WW, McDermott, M, Goldie, J, Cynader, M, Tan, J and Tufaro, F (1994). Selective destruction of gliomas in immunocompetent rats by thymidine kinase-defective herpes simplex virus type 1. J Natl Cancer Inst 86: 1209-1215.
9. Goldstein, DJ and Weller, SK (1988). Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virology 166: 41-51.
10. Aghi, M, Visted, T, Depinho, RA and Chiocca, EA (2008). Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16. Oncogene 27: 4249-4254.
11. Yamada, Y, Kimura, H, Morishima, T, Daikoku, T, Maeno, K and Nishiyama, Y (1991). The pathogenicity of ribonucleotide reductase-null mutants of herpes simplex virus type 1 in mice. J Infect Dis 164: 1091-1097.
12. Cameron, JM, McDougall, I, Marsden, HS, Preston, VG, Ryan, DM and Subak-Sharpe, JH (1988). Ribonucleotide reductase encoded by herpes simplex virus is a determinant of the pathogenicity of the virus in mice and a valid antiviral target. J Gen Virol 69 (Pt 10): 2607-2612.
13. Zhu, H, Dahlstrom, A and Hansson, HA (2005). Characterization of cell proliferation in the adult dentate under normal conditions and after kainate induced seizures using ribonucleotide reductase and BrdU. Brain Res 1036: 7-17.
14. Passer, BJ, Cheema, T, Zhou, B, Wakimoto, H, Zaupa, C, Razmjoo, M et al. (2010). Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication. Cancer Res 70: 3890-3895.
15. Petrowsky, H, Roberts, GD, Kooby, DA, Burt, BM, Bennett, JJ, Delman, KA et al. (2001). Functional interaction between fluorodeoxyuridine-induced cellular alterations and replication of a ribonucleotide reductase-negative herpes simplex virus. J Virol 75: 7050-7058.
16. Nakano, K, Todo, T, Zhao, G, Yamaguchi, K, Kuroki, S, Cohen, JB et al. (2005). Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models. J Gene Med 7: 638-648.
17. Walsh, D and Mohr, I (2006). Assembly of an active translation initiation factor complex by a viral protein. Genes Dev 20: 461-472.
18. Wang, X, Li, Y, Liu, S, Yu, X, Li, L, Shi, C et al. (2014). Direct activation of RIP3/MLKLdependent necrosis by herpes simplex virus 1 (HSV-1) protein ICP6 triggers host antiviral defense. Proc Natl Acad Sci USA 111: 15438-15443.
19. Dufour, F, Sasseville, AM, Chabaud, S, Massie, B, Siegel, RM and Langelier, Y (2011). The ribonucleotide reductase R1 subunits of herpes simplex virus types 1 and 2 protect cells against TNFa-and FasL-induced apoptosis by interacting with caspase-8. Apoptosis 16: 256-271.
20. Langelier, Y, Bergeron, S, Chabaud, S, Lippens, J, Guilbault, C, Sasseville, AM et al. (2002). The R1 subunit of herpes simplex virus ribonucleotide reductase protects cells against apoptosis at, or upstream of, caspase-8 activation. J Gen Virol 83(Pt 11): 2779-2789.
21. Mineta, T, Rabkin, SD and Martuza, RL (1994). Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res 54: 3963-3966.
22. Mineta, T, Rabkin, SD, Yazaki, T, Hunter, WD and Martuza, RL (1995). Attenuated multimutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1: 938-943.
23. Kanai, R, Zaupa, C, Sgubin, D, Antoszczyk, SJ, Martuza, RL, Wakimoto, H et al. (2012). Effect of 34.5 deletions on oncolytic herpes simplex virus activity in brain tumors. J Virol 86: 4420-4431.
24. Kanai, R, Wakimoto, H, Martuza, RL and Rabkin, SD (2011). A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells. Clin Cancer Res 17: 3686-3696.
25. Goldstein, DJ and Weller, SK (1988). Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 62: 196-205.
26. Pyles, RB and Thompson, RL (1994). Evidence that the herpes simplex virus type 1 uracil DNA glycosylase is required for efficient viral replication and latency in the murine nervous system. J Virol 68: 4963-4972.
27. Pyles, RB, Warnick, RE, Chalk, CL, Szanti, BE and Parysek, LM (1997). A novel multiplymutated HSV-1 strain for the treatment of human brain tumors. Hum Gene Ther 8: 533-544.
28. He, B, Gross, M and Roizman, B (1997). The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA 94: 843-848.
29. Silvera, D, Formenti, SC and Schneider, RJ (2010). Translational control in cancer. Nat Rev Cancer 10: 254-266.
30. He, B, Chou, J, Liebermann, DA, Hoffman, B and Roizman, B (1996). The carboxyl terminus of the murine MyD116 gene substitutes for the corresponding domain of the gamma(1)34.5 gene of herpes simplex virus to preclude the premature shutoff of total protein synthesis in infected human cells. J Virol 70: 84-90.
31. Bennett, JJ, Adusumilli, P, Petrowsky, H, Burt, BM, Roberts, G, Delman, KA et al. (2004). Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma134.5 deleted oncolytic herpes virus (G207). FASEB J 18: 1001-1003.
32. Aghi, M, Rabkin, S and Martuza, RL (2006). Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J Natl Cancer Inst 98: 38-50.
33. Aghi, MK, Liu, TC, Rabkin, S and Martuza, RL (2009). Hypoxia enhances the replication of oncolytic herpes simplex virus. Mol Ther 17: 51-56.
34. Talloczy, Z, Jiang, W, Virgin, HW 4th, Leib, DA, Scheuner, D, Kaufman, RJ et al. (2002). Regulation of starvation-and virus-induced autophagy by the eIF2alpha kinase signaling pathway. Proc Natl Acad Sci USA 99: 190-195.
35. Verpooten, D, Ma, Y, Hou, S, Yan, Z and He, B (2009). Control of TANK-binding kinase 1-mediated signaling by the gamma(1)34.5 protein of herpes simplex virus 1. J Biol Chem 284: 1097-1105.
36. Harland, J, Dunn, P, Cameron, E, Conner, J and Brown, SM (2003). The herpes simplex virus (HSV) protein ICP34.5 is a virion component that forms a DNA-binding complex with proliferating cell nuclear antigen and HSV replication proteins. J Neurovirol 9: 477-488.
37. Wang, Y, Yang, Y, Wu, S, Pan, S, Zhou, C, Ma, Y, et al. (2014). P32 is a novel target for ICP34.5 of herpes simplex virus type 1, and facilitates viral nuclear egress. J Biol Chem 289: 35795-805.
38. Bhutia, SK, Mukhopadhyay, S, Sinha, N, Das, DN, Panda, PK, Patra, SK et al. (2013). Autophagy: cancer's friend or foe Adv Cancer Res 118: 61-95.
39. Orvedahl, A, Alexander, D, Talloczy, Z, Sun, Q, Wei, Y, Zhang, W et al. (2007). HSV-1 ICP34.5 confers neurovirulence by targeting the Beclin 1 autophagy protein. Cell Host Microbe 1: 23-35.
40. Leib, DA, Alexander, DE, Cox, D, Yin, J and Ferguson, TA (2009). Interaction of ICP34.5 with Beclin 1 modulates herpes simplex virus type 1 pathogenesis through control of CD4+ T-cell responses. J Virol 83: 12164-12171.
41. Cheng, G, Brett, ME and He, B (2002). Signals that dictate nuclear, nucleolar, and cytoplasmic shuttling of the gamma(1)34.5 protein of herpes simplex virus type 1. J Virol 76: 9434-9445.
42. Chou, J, Kern, ER, Whitley, RJ and Roizman, B (1990). Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 250: 1262-1266.
43. Trgovcich, J, Johnson, D and Roizman, B (2002). Cell surface major histocompatibility complex class II proteins are regulated by the products of the gamma(1)34.5 and U(L)41 genes of herpes simplex virus 1. J Virol 76: 6974-6986.
44. Leib, DA, Machalek, MA, Williams, BR, Silverman, RH and Virgin, HW (2000). Specific phenotypic restoration of an attenuated virus by knockout of a host resistance gene. Proc Natl Acad Sci USA 97: 6097-6101.
45. Wakimoto, H, Kesari, S, Farrell, CJ, Curry, WT Jr, Zaupa, C, Aghi, M et al. (2009). Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res 69: 3472-3481.
46. Markert, JM, Medlock, MD, Rabkin, SD, Gillespie, GY, Todo, T, Hunter, WD et al. (2000). Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 7: 867-874.
47. Markert, JM, Razdan, SN, Kuo, HC, Cantor, A, Knoll, A, Karrasch, M et al. (2014). A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol Ther 22: 1048-1055.
48. Kambara, H, Okano, H, Chiocca, EA and Saeki, Y (2005). An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 65: 2832-2839.
49. Mohr, I and Gluzman, Y (1996). A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function. EMBO J 15: 4759-4766.
50. Mulvey, M, Poppers, J, Ladd, A and Mohr, I (1999). A herpesvirus ribosome-associated, RNA-binding protein confers a growth advantage upon mutants deficient in a GADD34-related function. J Virol 73: 3375-3385.
51. Shah, AC, Price, KH, Parker, JN, Samuel, SL, Meleth, S, Cassady, KA et al. (2006). Serial passage through human glioma xenografts selects for a Deltagamma134.5 herpes simplex virus type 1 mutant that exhibits decreased neurotoxicity and prolongs survival of mice with experimental brain tumors. J Virol 80: 7308-7315.
52. Shah, AC, Parker, JN, Gillespie, GY, Lakeman, FD, Meleth, S, Markert, JM et al. (2007). Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses. Gene Ther 14: 1045-1054.
53. Fu, X, Rivera, A, Tao, L and Zhang, X (2012). Incorporation of the B18R gene of vaccinia virus into an oncolytic herpes simplex virus improves antitumor activity. Mol Ther 20: 1871-1881.
54. Huard, B and Fruh, K (2000). A role for MHC class I down-regulation in NK cell lysis of herpes virus-infected cells. Eur J Immunol 30: 509-515.
55. Todo, T, Martuza, RL, Rabkin, SD and Johnson, PA (2001). Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA 98: 6396-6401.
56. Liu, BL, Robinson, M, Han, ZQ, Branston, RH, English, C, Reay, P et al. (2003). ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and antitumour properties. Gene Ther 10: 292-303.
57. Taneja, S, MacGregor, J, Markus, S, Ha, S and Mohr, I (2001). Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells. Proc Natl Acad Sci USA 98: 8804-8808.
58. Cassady, KA, Gross, M and Roizman, B (1998). The herpes simplex virus US11 protein effectively compensates for the gamma1(34.5) gene if present before activation of protein kinase R by precluding its phosphorylation and that of the alpha subunit of eukaryotic translation initiation factor 2. J Virol 72: 8620-8626.
59. Poppers, J, Mulvey, M, Khoo, D and Mohr, I (2000). Inhibition of PKR activation by the proline-rich RNA binding domain of the herpes simplex virus type 1 Us11 protein. J Virol 74: 11215-11221.
60. Mohr, I, Sternberg, D, Ward, S, Leib, D, Mulvey, M and Gluzman, Y (2001). A herpes simplex virus type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals. J Virol 75: 5189-5196.
61. Xing, J, Wang, S, Lin, R, Mossman, KL and Zheng, C (2012). Herpes simplex virus 1 tegument protein US11 downmodulates the RLR signaling pathway via direct interaction with RIG-I and MDA-5. J Virol 86: 3528-3540.
62. Lussignol, M, Queval, C, Bernet-Camard, MF, Cotte-Laffitte, J, Beau, I, Codogno, P et al. (2013). The herpes simplex virus 1 Us11 protein inhibits autophagy through its interaction with the protein kinase PKR. J Virol 87: 859-871.
63. Sanchez, R and Mohr, I (2007). Inhibition of cellular 2'-5' oligoadenylate synthetase by the herpes simplex virus type 1 Us11 protein. J Virol 81: 3455-3464.
64. Javouhey, E, Gibert, B, Arrigo, AP, Diaz, JJ and Diaz-Latoud, C (2008). Protection against heat and staurosporine mediated apoptosis by the HSV-1 US11 protein. Virology 376: 31-41.
65. Greco, A, Arata, L, Soler, E, Gaume, X, Coute, Y, Hacot, S et al. (2012). Nucleolin interacts with US11 protein of herpes simplex virus 1 and is involved in its trafficking. J Virol 86: 1449-1457.
66. Benetti, L and Roizman, B (2004). Herpes simplex virus protein kinase US3 activates and functionally overlaps protein kinase A to block apoptosis. Proc Natl Acad Sci USA 101: 9411-9416.
67. Chuluunbaatar, U, Roller, R, Feldman, ME, Brown, S, Shokat, KM and Mohr, I (2010). Constitutive mTORC1 activation by a herpesvirus Akt surrogate stimulates mRNA translation and viral replication. Genes Dev 24: 2627-2639.
68. Nguyen, ML and Blaho, JA (2007). Apoptosis during herpes simplex virus infection. Adv Virus Res 69: 67-97.
69. Liu, TC, Wakimoto, H, Martuza, RL and Rabkin, SD (2007). Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics. Clin Cancer Res 13: 5897-5902.
70. Kato, A, Tsuda, S, Liu, Z, Kozuka-Hata, H, Oyama, M and Kawaguchi, Y (2014). Herpes simplex virus 1 protein kinase Us3 phosphorylates viral dUTPase and regulates its catalytic activity in infected cells. J Virol 88: 655-666.
71. Imai, T, Sagou, K, Arii, J and Kawaguchi, Y (2010). Effects of phosphorylation of herpes simplex virus 1 envelope glycoprotein B by Us3 kinase in vivo and in vitro. J Virol 84: 153-162.
72. Wang, K, Ni, L, Wang, S and Zheng, C (2014). Herpes simplex virus 1 protein kinase US3 hyperphosphorylates p65/RelA and dampens NF-B activation. J Virol 88: 7941-7951.
73. Wang, S, Wang, K, Lin, R and Zheng, C (2013). Herpes simplex virus 1 serine/threonine kinase US3 hyperphosphorylates IRF3 and inhibits beta interferon production. J Virol 87: 12814-12827.
74. Liang, L and Roizman, B (2008). Expression of gamma interferon-dependent genes is blocked independently by virion host shutoff RNase and by US3 protein kinase. J Virol 82: 4688-4696.
75. Imai, T, Koyanagi, N, Ogawa, R, Shindo, K, Suenaga, T, Sato, A et al. (2013). Us3 kinase encoded by herpes simplex virus 1 mediates downregulation of cell surface major histocompatibility complex class I and evasion of CD8+ T cells. PLoS ONE 8: e72050.
76. Koyanagi, N, Imai, T, Arii, J, Kato, A and Kawaguchi, Y (2014). Role of herpes simplex virus 1 Us3 in viral neuroinvasiveness. Microbiol Immunol 58: 31-37.
77. Kasuya, H, Nishiyama, Y, Nomoto, S, Goshima, F, Takeda, S, Watanabe, I et al. (2007). Suitability of a US3-inactivated HSV mutant (L1BR1) as an oncolytic virus for pancreatic cancer therapy. Cancer Gene Ther 14: 533-542.
78. Boutell, C and Everett, RD (2013). Regulation of alphaherpesvirus infections by the ICP0 family of proteins. J Gen Virol 94(Pt 3): 465-481.
79. Sobol, PT, Hummel, JL, Rodrigues, RM and Mossman, KL (2009). PML has a predictive role in tumor cell permissiveness to interferon-sensitive oncolytic viruses. Gene Ther 16: 1077-1087.
80. Walsh, D and Mohr, I (2004). Phosphorylation of eIF4E by Mnk-1 enhances HSV-1 translation and replication in quiescent cells. Genes Dev 18: 660-672.
81. Hummel, JL, Safroneeva, E and Mossman, KL (2005). The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma. Mol Ther 12: 1101-1110.
82. Sobol, PT, Boudreau, JE, Stephenson, K, Wan, Y, Lichty, BD and Mossman, KL (2011). Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy. Mol Ther 19: 335-344.
83. Reinhart, B, Mazzacurati, L, Forero, A, Hong, CS, Eguchi, J, Okada, H et al. (2012). Inhibition of Indoleamine-2,3-dioxygenase (IDO) in Glioblastoma Cells by Oncolytic Herpes Simplex Virus. Adv Virol 2012: 815465.
84. Kehm, R, Rosen-Wolff, A and Darai, G (1996). Restitution of the UL56 gene expression of HSV-1 HFEM led to restoration of virulent phenotype; deletion of the amino acids 217 to 234 of the UL56 protein abrogates the virulent phenotype. Virus Res 40: 17-31.
85. Ushijima, Y, Luo, C, Goshima, F, Yamauchi, Y, Kimura, H and Nishiyama, Y (2007). Determination and analysis of the DNA sequence of highly attenuated herpes simplex virus type 1 mutant HF10, a potential oncolytic virus. Microbes Infect 9: 142-149.
86. Nawa, A, Luo, C, Zhang, L, Ushjima, Y, Ishida, D, Kamakura, M et al. (2008). Nonengineered, naturally oncolytic herpes simplex virus HSV1 HF-10: applications for cancer gene therapy. Curr Gene Ther 8: 208-221.
87. Wong, RJ, Patel, SG, Kim, S, DeMatteo, RP, Malhotra, S, Bennett, JJ et al. (2001). Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum Gene Ther 12: 253-265.
88. Mossman, KL and Smiley, JR (1999). Truncation of the C-terminal acidic transcriptional activation domain of herpes simplex virus VP16 renders expression of the immediateearly genes almost entirely dependent on ICP0. J Virol 73: 9726-9733.
89. Boviatsis, EJ, Scharf, JM, Chase, M, Harrington, K, Kowall, NW, Breakefield, XO et al. (1994). Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Ther 1: 323-331.
90. Miyatake, S, Iyer, A, Martuza, RL and Rabkin, SD (1997). Transcriptional targeting of herpes simplex virus for cell-specific replication. J Virol 71: 5124-5132.
91. Bertrand, L, Leiva-Torres, GA, Hyjazie, H and Pearson, A (2010). Conserved residues in the UL24 protein of herpes simplex virus 1 are important for dispersal of the nucleolar protein nucleolin. J Virol 84: 109-118.
92. Leiva-Torres, GA, Rochette, PA and Pearson, A (2010). Differential importance of highly conserved residues in UL24 for herpes simplex virus 1 replication in vivo and reactivation. J Gen Virol 91(Pt 5): 1109-1116.
93. Kelly, KJ, Wong, J and Fong, Y (2008). Herpes simplex virus NV1020 as a novel and promising therapy for hepatic malignancy. Expert Opin Investig Drugs 17: 1105-1113.
94. Workenhe, ST, Simmons, G, Pol, JG, Lichty, BD, Halford, WP and Mossman, KL (2014). Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy. Mol Ther 22: 123-131.
95. Smith, CC (2005). The herpes simplex virus type 2 protein ICP10PK: a master of versatility. Front Biosci 10: 2820-2831.
96. Colunga, AG, Laing, JM and Aurelian, L (2010). The HSV-2 mutant DeltaPK induces melanoma oncolysis through nonredundant death programs and associated with autophagy and pyroptosis proteins. Gene Ther 17: 315-327.
97. Fu, X, Tao, L, Cai, R, Prigge, J and Zhang, X (2006). A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus. Mol Ther 13: 882-890.
98. Fu, X, Tao, L and Zhang, X (2007). An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer. Cancer Gene Ther 14: 480-487.
99. Aurelian, L (2004). Herpes simplex virus type 2 vaccines: new ground for optimism Clin Diagn Lab Immunol 11: 437-445.
100. Aurelian, L, Kokuba, H and Smith, CC (1999). Vaccine potential of a herpes simplex virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase (ICP10). Vaccine 17: 1951-1963.
101. Morimoto, T, Arii, J, Tanaka, M, Sata, T, Akashi, H, Yamada, M et al. (2009). Differences in the regulatory and functional effects of the Us3 protein kinase activities of herpes simplex virus 1 and 2. J Virol 83: 11624-11634.
102. Mori, I (2012). Herpes simplex virus US3 protein kinase regulates host responses and determines neurovirulence. Microbiol Immunol 56: 351-355.
103. Rodrigues, R, Cuddington, B and Mossman, K (2010). Bovine herpesvirus type 1 as a novel oncolytic virus. Cancer Gene Ther 17: 344-355.
104. 104.Cuddington, BP and Mossman, KL (2014). Permissiveness of human cancer cells to oncolytic bovine herpesvirus 1 is mediated in part by KRAS activity. J Virol 88: 6885-6895.
105. Courchesne, MJ, White, MC, Stanfield, BA and Frampton, AR Jr (2012). Equine herpesvirus type 1-mediated oncolysis of human glioblastoma multiforme cells. J Virol 86: 2882-2886.
106. Lee, CY, Rennie, PS and Jia, WW (2009). MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells. Clin Cancer Res 15: 5126-5135.
107. Kuroda, T, Rabkin, SD and Martuza, RL (2006). Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector. Cancer Res 66: 10127-10135.
108. Yamamura, H, Hashio, M, Noguchi, M, Sugenoya, Y, Osakada, M, Hirano, N et al. (2001). Identification of the transcriptional regulatory sequences of human calponin promoter and their use in targeting a conditionally replicating herpes vector to malignant human soft tissue and bone tumors. Cancer Res 61: 3969-3977.
109. Pan, W, Bodempudi, V, Esfandyari, T and Farassati, F (2009). Utilizing ras signaling pathway to direct selective replication of herpes simplex virus-1. PLoS ONE 4: e6514.
110. Miyatake, SI, Tani, S, Feigenbaum, F, Sundaresan, P, Toda, H, Narumi, O et al. (1999). Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo. Gene Ther 6: 564-572.
111. Mullen, JT, Kasuya, H, Yoon, SS, Carroll, NM, Pawlik, TM, Chandrasekhar, S et al. (2002). Regulation of herpes simplex virus 1 replication using tumor-associated promoters. Ann Surg 236: 502-12; discussion 512.
112. Longo, SL, Griffith, C, Glass, A, Shillitoe, EJ and Post, DE (2011). Development of an oncolytic herpes simplex virus using a tumor-specific HIF-responsive promoter. Cancer Gene Ther 18: 123-134.
113. Chung, RY, Saeki, Y and Chiocca, EA (1999). B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells. J Virol 73: 7556-7564.
114. Nakamura, H, Kasuya, H, Mullen, JT, Yoon, SS, Pawlik, TM, Chandrasekhar, S et al. (2002). Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5. J Clin Invest 109: 871-882.
115. Bolyard, C, Yoo, JY, Wang, PY, Saini, U, Rath, KS, Cripe, TP et al. (2014). Doxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer. Clin Cancer Res 20: 6479-6494.
116. Krupkova, O Jr, Loja, T, Zambo, I and Veselska, R (2010). Nestin expression in human tumors and tumor cell lines. Neoplasma 57: 291-298.
117. Yoo, JY, Haseley, A, Bratasz, A, Chiocca, EA, Zhang, J, Powell, K et al. (2012). Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus. Mol Ther 20: 287-297.
118. Kanai, R, Tomita, H, Hirose, Y, Ohba, S, Goldman, S, Okano, H et al. (2007). Augmented therapeutic efficacy of an oncolytic herpes simplex virus type 1 mutant expressing ICP34.5 under the transcriptional control of musashi1 promoter in the treatment of malignant glioma. Hum Gene Ther 18: 63-73.
119. Maldonado, AR, Klanke, C, Jegga, AG, Aronow, BJ, Mahller, YY, Cripe, TP et al. (2010). Molecular engineering and validation of an oncolytic herpes simplex virus type 1 transcriptionally targeted to midkine-positive tumors. J Gene Med 12: 613-623.
120. Mazzacurati, L, Marzulli, M, Reinhart, B, Miyagawa, Y, Uchida, H, Goins, WF et al. (2015). Use of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSV. Mol Ther 23: 99-107.
121. Fu, X, Rivera, A, Tao, L, De Geest, B and Zhang, X (2012). Construction of an oncolytic herpes simplex virus that precisely targets hepatocellular carcinoma cells. Mol Ther 20: 339-346.
122. Campadelli-Fiume, G, Menotti, L, Avitabile, E and Gianni, T (2012). Viral and cellular contributions to herpes simplex virus entry into the cell. Curr Opin Virol 2: 28-36.
123. Grandi, P, Fernandez, J, Szentirmai, O, Carter, R, Gianni, D, Sena-Esteves, M et al. (2010). Targeting HSV-1 virions for specific binding to epidermal growth factor receptor-vIIIbearing tumor cells. Cancer Gene Ther 17: 655-663.
124. Zhou, G and Roizman, B (2005). Characterization of a recombinant herpes simplex virus 1 designed to enter cells via the IL13Ralpha2 receptor of malignant glioma cells. J Virol 79: 5272-5277.
125. Zhou, G and Roizman, B (2006). Construction and properties of a herpes simplex virus 1 designed to enter cells solely via the IL-13alpha2 receptor. Proc Natl Acad Sci USA 103: 5508-5513.
126. Menotti, L, Nicoletti, G, Gatta, V, Croci, S, Landuzzi, L, De Giovanni, C et al. (2009). Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. Proc Natl Acad Sci USA 106: 9039-9044.
127. Uchida, H, Marzulli, M, Nakano, K, Goins, WF, Chan, J, Hong, CS et al. (2013). Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFRretargeted oncolytic herpes simplex virus. Mol Ther 21: 561-569.
128. Baek, H, Uchida, H, Jun, K, Kim, JH, Kuroki, M, Cohen, JB et al. (2011). Bispecific adaptermediated retargeting of a receptor-restricted HSV-1 vector to CEA-bearing tumor cells. Mol Ther 19: 507-514.
129. Nanni, P, Gatta, V, Menotti, L, De Giovanni, C, Ianzano, M, Palladini, A et al. (2013). Preclinical therapy of disseminated HER-2 ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. PLoS Pathog 9: e1003155.
130. Gambini, E, Reisoli, E, Appolloni, I, Gatta, V, Campadelli-Fiume, G, Menotti, L et al. (2012). Replication-competent herpes simplex virus retargeted to HER2 as therapy for highgrade glioma. Mol Ther 20: 994-1001.
131. Reisoli, E, Gambini, E, Appolloni, I, Gatta, V, Barilari, M, Menotti, L et al. (2012). Efficacy of HER2 retargeted herpes simplex virus as therapy for high-grade glioma in immunocompetent mice. Cancer Gene Ther 19: 788-795.
132. Terada, K, Wakimoto, H, Tyminski, E, Chiocca, EA and Saeki, Y (2006). Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. Gene Ther 13: 705-714.
133. Fukuhara, H, Ino, Y, Kuroda, T, Martuza, RL and Todo, T (2005). Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system. Cancer Res 65: 10663-10668.
134. Kuroda, T, Martuza, RL, Todo, T and Rabkin, SD (2006). Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases. BMC Biotechnol 6: 40.
135. Jeyaretna, DS and Kuroda, T (2007). Recent advances in the development of oncolytic HSV-1 vectors: 'arming' of HSV-1 vectors and application of bacterial artificial chromosome technology for their construction. Curr Opin Mol Ther 9: 447-466.
136. Castelo-Branco, P, Passer, BJ, Buhrman, JS, Antoszczyk, S, Marinelli, M, Zaupa, C et al. (2010). Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer. Gene Ther 17: 805-810.
137. Tischer, BK and Kaufer, BB (2012). Viral bacterial artificial chromosomes: generation, mutagenesis, and removal of mini-F sequences. J Biomed Biotechnol 2012: 472537.
138. Bi, Y, Sun, L, Gao, D, Ding, C, Li, Z, Li, Y et al. (2014). High-efficiency targeted editing of large viral genomes by RNA-guided nucleases. PLoS Pathog 10: e1004090.
139. Suenaga, T, Kohyama, M, Hirayasu, K and Arase, H (2014). Engineering large viral DNA genomes using the CRISPR-Cas9 system. Microbiol Immunol 58: 513-522.
140. Cheema, TA, Wakimoto, H, Fecci, PE, Ning, J, Kuroda, T, Jeyaretna, DS et al. (2013). Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proc Natl Acad Sci USA 110: 12006-12011.
141. Argnani, R, Marconi, P, Volpi, I, Bolanos, E, Carro, E, Ried, C et al. (2011). Characterization of herpes simplex virus 1 strains as platforms for the development of oncolytic viruses against liver cancer. Liver Int 31: 1542-1553.
142. Yamamoto, S, Deckter, LA, Kasai, K, Chiocca, EA and Saeki, Y (2006). Imaging immediateearly and strict-late promoter activity during oncolytic herpes simplex virus type 1 infection and replication in tumors. Gene Ther 13: 1731-1736.
143. Adusumilli, PS, Stiles, BM, Chan, MK, Eisenberg, DP, Yu, Z, Stanziale, SF et al. (2006). Realtime diagnostic imaging of tumors and metastases by use of a replication-competent herpes vector to facilitate minimally invasive oncological surgery. FASEB J 20: 726-728.
144. Carpenter, S and Fong, Y (2012). Real-time fluorescence imaging of abdominal, pleural, and lymphatic metastases. Methods Mol Biol 872: 141-157.
145. Li, H, Nakashima, H, Decklever, TD, Nace, RA and Russell, SJ (2013). HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy. Cancer Gene Ther 20: 478-485.
146. Todo, T, Rabkin, SD and Martuza, RL (2000). Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors. Cancer Gene Ther 7: 939-946.
147. Nakamura, H, Mullen, JT, Chandrasekhar, S, Pawlik, TM, Yoon, SS and Tanabe, KK (2001). Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. Cancer Res 61: 5447-5452.
148. Guffey, MB, Parker, JN, Luckett, WS Jr, Gillespie, GY, Meleth, S, Whitley, RJ et al. (2007). Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors. Cancer Gene Ther 14: 45-56.
149. Chase, M, Chung, RY and Chiocca, EA (1998). An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat Biotechnol 16: 444-448.
150. Tyminski, E, Leroy, S, Terada, K, Finkelstein, DM, Hyatt, JL, Danks, MK et al. (2005). Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan. Cancer Res 65: 6850-6857.
151. Braidwood, L, Dunn, PD, Hardy, S, Evans, TR and Brown, SM (2009). Antitumor activity of a selectively replication competent herpes simplex virus (HSV) with enzyme prodrug therapy. Anticancer Res 29: 2159-2166.
152. Bharara, S, Sorscher, EJ, Gillespie, GY, Lindsey, JR, Hong, JS, Curlee, KV et al. (2005). Antibiotic-mediated chemoprotection enhances adaptation of E. coli PNP for herpes simplex virus-based glioma therapy. Hum Gene Ther 16: 339-347.
153. Cheema, TA, Kanai, R, Kim, GW, Wakimoto, H, Passer, B, Rabkin, SD et al. (2011). Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts. Clin Cancer Res 17: 7383-7393.
154. Kulu, Y, Kawasaki, H, Donahue, JM, Kasuya, H, Cusack, JC, Choi, EW et al. (2013). Concurrent chemotherapy inhibits herpes simplex virus-1 replication and oncolysis. Cancer Gene Ther 20: 133-140.
155. Tamura, K, Wakimoto, H, Agarwal, AS, Rabkin, SD, Bhere, D, Martuza, RL et al. (2013). Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors. Mol Ther 21: 68-77.
156. Lichty, BD, Breitbach, CJ, Stojdl, DF and Bell, JC (2014). Going viral with cancer immunotherapy. Nat Rev Cancer 14: 559-567.
157. Fulci, G, Breymann, L, Gianni, D, Kurozomi, K, Rhee, SS, Yu, J et al. (2006). Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci USA 103: 12873-12878.
158. Alvarez-Breckenridge, CA, Yu, J, Price, R, Wojton, J, Pradarelli, J, Mao, H et al. (2012). NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat Med 18: 1827-1834.
159. Toda, M, Rabkin, SD, Kojima, H and Martuza, RL (1999). Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther 10: 385-393.
160. Li, H, Dutuor, A, Fu, X and Zhang, X (2007). Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model. J Gene Med 9: 161-169.
161. Varghese, S, Rabkin, SD, Liu, R, Nielsen, PG, Ipe, T and Martuza, RL (2006). Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Ther 13: 253-265.
162. Malhotra, S, Kim, T, Zager, J, Bennett, J, Ebright, M, D'Angelica, M et al. (2007). Use of an oncolytic virus secreting GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas. Surgery 141: 520-529.
163. Kaufman, HL, Kim, DW, DeRaffele, G, Mitcham, J, Coffin, RS and Kim-Schulze, S (2010). Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 17: 718-730.
164. Hersey, P and Gallagher, S (2014). Intralesional immunotherapy for melanoma. J Surg Oncol 109: 320-326.
165. Lasek, W, Zagozdzon, R and Jakobisiak, M (2014). Interleukin 12: still a promising candidate for tumor immunotherapy Cancer Immunol Immunother 63: 419-435.
166. Parker, JN, Gillespie, GY, Love, CE, Randall, S, Whitley, RJ and Markert, JM (2000). Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci USA 97: 2208-2213.
167. Varghese, S, Rabkin, SD, Nielsen, PG, Wang, W and Martuza, RL (2006). Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung. Clin Cancer Res 12: 2919-2927.
168. Antoszczyk, S, Spyra, M, Mautner, VF, Kurtz, A, Stemmer-Rachamimov, AO, Martuza, RL et al. (2014). Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus. Neuro-oncology 16: 1057-1066.
169. Roth, JC, Cassady, KA, Cody, JJ, Parker, JN, Price, KH, Coleman, JM et al. (2014). Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates. Hum Gene Ther Clin Dev 25: 16-27.
170. Zhang, W, Fulci, G, Wakimoto, H, Cheema, TA, Buhrman, JS, Jeyaretna, DS et al. (2013). Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models. Neoplasia 15: 591-599.
171. Andreansky, S, He, B, van Cott, J, McGhee, J, Markert, JM, Gillespie, GY et al. (1998). Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther 5: 121-130.
172. Pyonteck, SM, Akkari, L, Schuhmacher, AJ, Bowman, RL, Sevenich, L, Quail, DF et al. (2013). CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 19: 1264-1272.
173. Zhang, W, Fulci, G, Buhrman, JS, Stemmer-Rachamimov, AO, Chen, JW, Wojtkiewicz, GR et al. (2012). Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma. Mol Ther 20: 37-45.
174. Zhang, G, Jin, G, Nie, X, Mi, R, Zhu, G, Jia, W et al. (2014). Enhanced antitumor efficacy of an oncolytic herpes simplex virus expressing an endostatin-angiostatin fusion gene in human glioblastoma stem cell xenografts. PLoS ONE 9: e95872.
175. Liu, TC, Zhang, T, Fukuhara, H, Kuroda, T, Todo, T, Martuza, RL et al. (2006). Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. Mol Ther 14: 789-797.
176. Hardcastle, J, Kurozumi, K, Dmitrieva, N, Sayers, MP, Ahmad, S, Waterman, P et al. (2010). Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. Mol Ther 18: 285-294.
177. Tsuji, T, Nakamori, M, Iwahashi, M, Nakamura, M, Ojima, T, Iida, T et al. (2013). An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer. Int J Cancer 132: 485-494.
178. Goodwin, JM, Schmitt, AD, McGinn, CM, Fuchs, BC, Kuruppu, D, Tanabe, KK et al. (2012). Angiogenesis inhibition using an oncolytic herpes simplex virus expressing endostatin in a murine lung cancer model. Cancer Invest 30: 243-250.
179. Dmitrieva, N, Yu, L, Viapiano, M, Cripe, TP, Chiocca, EA, Glorioso, JC et al. (2011). Chondroitinase ABC I-mediated enhancement of oncolytic virus spread and antitumor efficacy. Clin Cancer Res 17: 1362-1372.
180. Mahller, YY, Vaikunth, SS, Ripberger, MC, Baird, WH, Saeki, Y, Cancelas, JA et al. (2008). Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors. Cancer Res 68: 1170-1179.
181. Kanai, R, Wakimoto, H, Cheema, T and Rabkin, SD (2010). Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer Future Oncol 6: 619-634.
182. MacLean, AR, ul-Fareed, M, Robertson, L, Harland, J and Brown, SM (1991). Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence. J Gen Virol 72 (Pt 3): 631-639.
183. Sgubin, D, Wakimoto, H, Kanai, R, Rabkin, SD and Martuza, RL (2012). Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells. Stem Cells Transl Med 1: 322-332.
184. Wong, RJ, Joe, JK, Kim, SH, Shah, JP, Horsburgh, B and Fong, Y (2002). Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases. Hum Gene Ther 13: 1213-1223.